Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial by Rosche, B. et al.
TRIALS
Rosche et al. Trials 2013, 14:112
http://www.trialsjournal.com/content/14/1/112STUDY PROTOCOL Open AccessTrichuris suis ova in relapsing-remitting multiple
sclerosis and clinically isolated syndrome
(TRIOMS): study protocol for a randomized
controlled trial
Berit Rosche1,2*, Klaus-Dieter Wernecke3, Stephanie Ohlraun4, Jan-Markus Dörr2,4 and Friedemann Paul2,4,5Abstract
Background: Trichuris suis ova is a probiotic treatment based on the hygiene hypothesis. It has been demonstrated
as safe and effective in autoimmune inflammatory bowel diseases and clinical trials indicate that helminth
infections also have an immunomodulatory effect in multiple sclerosis.
We hypothesize that administering 2,500 Trichuris suis ova eggs orally every two weeks for 12 months is - due to its
immunomodulatory and anti-inflammatory effect - significantly more effective than oral placebo in preventing new
T2 and Gd+ lesions, as quantified by cerebral MRI and clinical examination, in relapsing-remitting multiple sclerosis
and clinically isolated syndrome.
Methods/Design: Fifty patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome with
clinical activity, not undergoing any standard therapies, will be randomized 1:1 to Trichuris suis ova 2,500 eggs every
two weeks or matching placebo. The safety, tolerability and effect on disease activity and in vivo mechanisms of
action of Trichuris suis ova in MS will be assessed by neurological, laboratory and immunological exams and
magnetic resonance imaging throughout the 12-month treatment period and over a follow-up period of 6 months.
Various immunological analyses will be used to assess the overall patient immune response prior to and at varying
time points following treatment with Trichuris suis ova.
Discussion: We anticipate that Trichuris suis ova will be well tolerated and more effective than the placebo in
preventing new T2 and Gd+ lesions, as quantified by MRI. We also expect the Th1/Th17 proinflammatory response
to shift towards the more anti-inflammatory Th2 response. This study has important clinical implications and will
involve extensive research on the immunology of helminth therapy.
Trial registration: ClinicalTrials.gov: NCT01413243
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Multiple sclerosis (MS) is a chronic inflammatory dis-
ease of the central nervous system (CNS), whose inci-
dence has increased over recent decades [1] and which
features a specific geographical distribution with higher
incidence rates in developed Western nations [2,3].* Correspondence: berit.rosche@charite.de
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reproduction in any medium, provided the orAlthough the etiology remains unclear, MS is widely
assumed to be an autoimmune disease, in which both
genetic susceptibility and environmental factors play a
role [4]. In 1966, Leibowitz et al. first suggested that MS
might be associated with high sanitation standards
during childhood [5], and subsequent epidemiological
surveys have confirmed high MS prevalence in regions
where such standards are the norm [6]. Beneficial
immunomodulation by helminths in humans has been dem-
onstrated in an observational study of relapsing-remitting
(RR) MS patients with asymptomatic, community-acquiredLtd. This is an Open Access article distributed under the terms of the Creative
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fected MS patients, parasite-infected patients showed a
significantly lower number of exacerbations, stable dis-
ability scores, and fewer new T2 and gadolinium en-
hancing (Gd+) lesions in brain magnetic resonance
imaging (MRI). Consequently, new treatment para-
digms based on the hygiene hypothesis were developed
for autoimmune diseases, including the administering of
non-pathogenic live microorganisms. The first clinical tri-
als using Trichuris suis ova (TSO), a pig whipworm that is
non-pathogenic in humans, in autoimmune diseases, such
as inflammatory bowel disease, showed good tolerability
and a striking suppressive effect on the autoimmune
response [8]. Recently, Fleming et al. completed a phase I
controlled trial that showed significant reduction of dis-
ease activity in RRMS patients under treatment with TSO
[9]. We have also analyzed the effects of TSO in four
patients with secondary progressive MS and observed a
slight down-regulation of the Th1-associated cytokine
pattern, especially interleukin (IL)-2, with a temporary
increase of Th2-associated cytokines, such as IL-4. Fur-
thermore, mild eosinophilia and changes in CD4+ and
CD8+ T cells and natural killer (NK) CD56 bright cell
numbers were evident [10].
A number of different hypotheses currently seek to ex-
plain how helminths influence autoimmune disorders. An
increase in IL-10 and transforming growth factor-β and a
decrease in IL-12 and interferon-γ-secreting cells have
been shown in fresh peripheral blood mononuclear cells
(PBMCs) of MS patients with a helminth infection [7]. The
patients also had a higher number of CD4+CD25+FoxP3+
regulatory T cells [7] and IL-10-producing CD19+ B cells
[11]. The B cells also produced higher levels of brain-
derived neurotrophic factor and nerve growth factor. In
the MS animal model experimental autoimmune enceph-
alomyelitis (EAE), a reduced incidence and delayed on-
set of disease after infection with Schistosoma mansoni
was seen, probably as a result of down-regulation of
proinflammatory cytokines [12].
Overall, this research suggests that TSO is a promising
therapeutic option in RRMS. We plan to investigate this
further in a monocentric, prospective, randomized,
placebo-controlled, double-blind phase II pilot study in
patients with RRMS or clinically isolated syndrome (CIS)
[13] using MRI and clinical assessment, and hypothesize
that oral administration of 2,500 embryonated TSO every
two weeks is superior to placebo administration.
Methods/Design
Trial design
TRIOMS is a monocentric, prospective, randomized,
placebo-controlled, double-blind, phase II pilot study to
be conducted at the Department of Neurology and the
NeuroCure Clinical Research Center of the Charité -Universitätsmedizin Berlin. We plan to begin recruit-
ment in Summer 2012. Fifty patients with RRMS or CIS,
who have not undergone immunomodulatory treatment
for at least 3 months, will be randomized to either TSO
2,500 ova or placebo to be taken every two weeks for 12
months as an immunomodulatory monotherapy. The
detailed study design is based on the revised Consoli-
dated Standards of Reporting Trials Statement [14,15].
The study is approved by the local ethics committee
and the German competent authority (Federal Institute
for Drugs and Medical Devices). The trial is registered at
Clinicaltrials.gov (NCT01413243) and will be conducted
in accordance with the Declaration of Helsinki in its
currently applicable version, the guidelines of the Inter-
national Conference on Harmonization of Good Clinical
Practice (ICH-GCP), and the applicable German laws.
All participants will be required to give written in-
formed consent. The trial will be monitored according
to ICH-GCP.
Participants
The inclusion criteria for participation in the TRIOMS
trial comprise the diagnosis of either definite RRMS
according to the revised 2005 McDonald criteria [16] or
CIS, an age of 18 to 65 years, a score of ≤4.0 on the Ex-
panded Disability Status Scale (EDSS) [17], and disease
activity on brain MRI (Table 1).
The main exclusion criteria include any disease course
other than RRMS or CIS, any disease other than MS that
may better explain the symptoms and signs, any immuno-
modulatory or immunosuppressive treatment, such as
interferon-β, mitoxantrone, glatiramer acetate, natalizumab,
within the preceding three months. Additionally, the partic-
ipants must not have any significant uncontrolled disease,
such as neoplasia or cardiovascular, renal, hepatic, endo-
crine or gastrointestinal disease or any other significant dis-
ease that may preclude the patient from participating in the
study (Table 1).
Randomization and interventions
The eligibility of patients will be determined at the
screening visit. At the baseline visit, patients who quali-
fied for participation in the study will be stratified
according to gender and disease course (RRMS/CIS) and
randomized 1:1 into the two intervention groups. One
group will receive TSO 2,500 eggs orally every 14 days,
the other a placebo suspension orally every 14 days.
Visits will be carried out after 3, 6, 9 and 12 months
(Table 2). To ensure reliable monitoring of tolerability,
telephone check-ups are planned after every dispensa-
tion if a patient does not visit the study center, because
prior studies have shown frequent gastrointestinal
adverse events or symptoms after therapy with TSO
[18]. Optional follow-up visits will be offered at 15 and
Table 1 Eligibility criteria
Key inclusion
criteria
Diagnosis of RRMS in accordance to the revised
McDonald criteria (2005) or CIS
Aged 18 to 65 years, inclusive
Expanded Disability Status Scale (EDSS) at screening
score ≤4.0
Ability to provide written informed consent
Disease activity on brain defined by:
(A) ≥1 gadolinium enhancing lesion on screening
MRI or another MRI performed in the 12 months
prior to screening OR
(B) ≥1 new T2 lesion on screening MRI or on another
MRI performed in the 12 months prior to screening
in comparison to an earlier MRI performed in the
previous 36 months OR
(C) ≥1 enlarging T2 lesion on screening MRI or on
another MRI performed in the 12 months before
screening in comparison to an earlier MRI performed
in the previous 36 months
Adequate birth control by a contraception method
with a PEARL-index <1 in women of childbearing
potential
Contraindication or intolerance for established
standard immunomodulatory treatments with
interferon-β or glatiramer acetate
Information about established standard
immunomodulatory treatments for MS by an
independent neurologist and explicit decision of the
patient against these treatment
Stable neurological state at study inclusion without
any signs of a relapse and without steriod therapy in
the last 30 days
Key exclusion
criteria
Any disease other than MS that may better explain
the symptoms and signs
Any other immunomodulatory or
immunosuppressive treatment, for example,
interferon-β, mitoxantrone, glatiramer acetate,
natalizumab within the preceding three months
Any significant uncontrolled disease, such as
neoplasia, relevant liver disorder, active hepatitis B or
C, and reduced liver function
Relevant laboratory findings:
• aspartate aminotransferase/alanine
aminotransferase (ASAT/ALAT) >3 times of
reference value
• bilirubine >1.5 mg/dl
• hemoglobin <8.5 g/dl
• white blood count <2.5/nl
• thrombocytes <125/nl
• creatinine-clearance according to Cockroft-Gault
-formula <110 ml/min (male) and <95 ml/min
(female)
Any severe medical conditions or additional
autoimmune disease which requires a
immunosuppressive or immunomodulatory treatment
Any psychiatric or other condition that impedes the
ability to provide informed consent or patient’s
compliance
Table 1 Eligibility criteria (Continued)
Refusal of transmission of personal data
Inability to complete an MRI scan
Relapse within 30 days of trial entry
Known allergies against components of TSO or
placebo
Participation in any interventional clinical trial in the
last three months or during the participant in
TRIOMS
Pregnancy or breast feeding
Concomitant medication with antihelminthic therapy
History of small intestinal resection
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unscheduled visits can be performed at any time.Outcome parameters
The primary endpoint is the cumulative number of new
hyperintense lesions identified on T2-weighted brain
MRI during the treatment period of 12 months. Add-
itional secondary MRI endpoints comprise the volume
of T2 hyperintense lesions and number and volume of
contrast-enhancing T1 hypointense lesions, the propor-
tion of patients without any new T1 hypointense and T2
hyperintense lesions, brain atrophy as determined by
brain parenchymal fraction and normalized brain
volume 18 [19], and changes in brain metabolism
(NAA/Cr-quotient) as determined by MR spectroscopy
[20,21]. All MRI investigations will be performed using a
3 Tesla MRI scanner (Siemens Healthcare, Erlangen,
Germany. Other secondary clinical endpoints include
the annualized relapse rate and the proportion of
relapse-free patients. A relapse is defined as de novo de-
velopment, aggravation or re-occurrence of a pre-
existing neurological abnormality compatible with MS,
which lasts a minimum of 24 hours, is separated by at
least 30 days from a preceding clinical event and does
not occur in the context of fever or infection. Further
secondary endpoints are the disease progression as de-
termined by EDSS (evaluated by an independent neur-
ologist) [17], Multiple Sclerosis Functional Composite
(MSFC) [22], depression as determined by the Beck De-
pression Inventory (BDI) [23] and fatigue as determined
by the Fatigue Severity Scale (FSS) [24]. Assessment of
all clinical and MRI endpoints will be performed by
experienced evaluators blinded to both the clinical data
and treatment allocation. Peripheral venous blood
(serum, heparinized blood for flow cytometry and PBMC
isolation) will be sampled prior to and during the inter-
vention to assess the effect on cellular and soluble com-
ponents of the immune system. In detail, we plan to
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Relapse history x x x x x x x x
Medical history x x x x x x x x
Physical examination x x x x x x
Vital signs x x x x x x x
Weight x x x
MSFC x x x
EDSS x x x x x x x
Safety lab x x x x x x
Immunological
sampling
x x x x x x
MRI x x x x optional optional
AE/SAE x x x x x x
Questionnaires
(fatigue, depression)
x x x x x x x
Drug supply x x x x x
Drug account x x
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stimulation of fresh heparinized blood and determination of
cytokines using the cytokine bead array. In fresh heparinized
blood, we will measure the frequency of B cells, CD4+ and
CD8+ Tcell subpopulations, innate immune cells and quan-
tify the activation and homing markers on these cells by
multicolor flow cytometry. We will also assess the number
of IL-10-producing B cells by stimulation of fresh isolated
PBMCs with 0.1 mg/ml CpG ODN2006 for 72 hr and will
add phorbol myristate acetate and ionomycin (PMA+iono)
for the last 6 hr and brefeldin A for the last 4 hr in order to
block cytokine excretion. Detection of IL-10 producing cells
is planned as intracellular staining of IL-10 on CD 19 ex-
pressing cells by multicolor flow cytometry. Alternatively,
IL-10 we will be measured in the culture supernatants by
ELISA with aliquots of supernatant taken from cell cultures
before the addition of brefeldin A and PMA+iono to the
cultures.
Sample size
Because the present data on the effect of TSO on the de-
velopment of new T2 hyperintense lesions on brainMRI, which is the primary endpoint of the TRIOMS
study, are insufficient for an exact statistical sample size
calculation, we have designed the investigation as a pilot
study with an a priori determined sample size of 25
patients per intervention arm, giving a total of 50
patients. The results of this exploratory analysis could
serve as the basis for a further prospective randomized
study with a statistically justified sample size.
Blinding
Both the patients and all study personnel will remain
blinded throughout the complete treatment period of 12
months. Treatment allocations will only be disclosed
after the final database lock or in case of emergency.
The active study therapy and placebo bottles will be
supplied by OVAMED GmbH and labeling of bottles
and randomization of patients will be performed in the
central pharmacy of the Charité - Universitätsmedizin
Berlin. The patients will mainly be attended to by a
“treating physician”, responsible for evaluating the inclu-
sion or exclusion criteria, adverse events, relapses, side
effects and so on. All neurological examinations will be
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separate the physicians’ function in a threating and an
evaluating position in order to prevent unblinding is ne-
cessary because patients under therapy with TSO com-
monly report gastrointestinal side effects that may point
the physician to the verum therapy. Similarly, evaluation
of all other paraclinical parameters, including MRI, will
be conducted by independent examiners. Any patient-
related crosstalk between treating and evaluating physi-
cians or examiners will be prohibited unless required for
safety reasons. A simple unblinding procedure has been
designed, which allows for rapid unblinding of a patient
in case of a medical necessity. If the patient is unblinded,
he or she will be automatically excluded from the study.
Statistical methods
Endpoints will be evaluated by both intention-to-treat-
and per-protocol-analyses. Statistical tests and presenta-
tion will be appropriate to the scaling and distribution of
the respective variables. Because TRIOMS is planned as
a pilot study, there is a statistical analysis of endpoints,
but P-values will be considered exploratively without
confirming generalization of hypotheses about the study
treatments. Due to the restricted sample size of the pilot
study, sufficiently powerful statistical analysis is not pos-
sible. The primary end point will be analyzed using Fish-
er’s exact test. Secondary endpoints will be analyzed
non-parametrically using Mann–Whitney-U-test, due to
the small sample size and possible deviations from nor-
mality. Frequencies will be compared with the Fisher’s
exact test.Because of the exploratory character of the
analysis, alpha-adjusting will not be performed. The test
level for statistical significance of differences between
both treatment arms is defined as P = 0.05 (two-sided)
for all tests. For statistical analyses use of the following
software is planned: SAS, version 9.4 (SAS Institute Inc.
Cary, North Carolina, US); SPSS, version 20 (IBM,
Armonk, New York, US) and StatXact 6 from CYTEL
(Cytel Inc., Cambridge, Massachusetts, US).
Discussion
Approved medications for MS, such as beta interferons
or glatiramer acetate have limited therapeutic efficacy or,
in the case of natalizumab, mitoxantrone or fingolimod,
may be associated with severe side effects. The ideal
drug for patients with MS should be highly effective with
few and clinically insignificant side effects and should be
administered orally. Existing epidemiological and pre-
clinical data suggest that helminth infections are protect-
ive in autoimmune diseases, such as MS, and the first
clinical trials with oral administration of pig whipworm
Trichuris suis eggs in MS revealed good tolerance and
surprising clinical effects [9,10]. Mechanisms of how hel-
minth infections provide protection in autoimmunediseases are manifold and comprise immunosuppression
attributed to an increased activity of regulatory T cells
(Treg cells), alternatively activated macrophages and,
more recently, IL-10 producing regulatory B cells. Fur-
ther, helminth infections induce the production of Th2
related cytokines, such as IL-4, IL-5, IL-9 and IL-13,
with anti-inflammatory qualities [25]. In addition, com-
petitive mechanisms for antigen processing, antigen
binding and for essential cytokines may exist between
anti-infectious and autoimmune responses [26].
Here, we present a study design that has the potential
to substantially contribute to the evaluation of the effi-
cacy and tolerance of TSO in MS patients. The random-
ized, controlled, double-blind study design and the
implementation of independent evaluation of outcome
parameters fulfill the current criteria for a high quality
clinical phase II trial in MS [14,15]. A limited sample
size was chosen to reduce the number of patients on
placebo and on a possibly ineffective therapy. On the
other hand, this limited sample size may not be suffi-
cient to show a statistically significant superiority of
TSO compared with placebo. The placebo design was
chosen to evaluate the sole effect of TSO on MS activity
and to minimize the risk of uncontrolled immunosup-
pression that could be relevant in a treatment with TSO
and other immunosuppressive or immunomodulatory
therapies. Fleming et al. showed a reduction of Gd+
lesions in MRI under therapy with TSO in MS patients
after three months of therapy and an increase of lesions
in the post-treatment period, suggesting that a perman-
ent therapy is desirable for treatment of a chronic dis-
ease like MS [9]. Therefore, we have chosen a relatively
long therapy duration of 12 months to confirm on the
one hand the clinical effects of TSO on MS activity and
to show on the other hand that this medication fulfills
safety aspects for long time use.
In conclusion, TSO has the potential as an effective,
safe and orally available treatment option in MS and the
TRIOMS trial may help to establish the first probiotic
therapy in MS that is based on the hygiene hypothesis.Trial status
Start of recruitment September 2012.
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